Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism.

By D. Jiménez, D. Aujesky, L. Moores, V. Gómez, J. Lobo, F. Uresandi, R. Otero, M. Monreal, A. Muriel, R. Yusen. Archives of Internal Medicine, 2010

1,280 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Internal Medicine

View Paper: https://www.semanticscholar.org/paper/3943718050ac34e84bad5145873bd8357859640c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. S. Schulman
2. G. Agnelli
3. Jeroen J. Bax
4. Jose Luis Zamorano
5. P. Lancellotti

In Epidemiology

1. Jeroen J. Bax
2. Jose Luis Zamorano
3. P. Lancellotti

In Internal Medicine

1. G. Agnelli
2. S. Konstantinides
3. H. Büller

Citations in the corpus

• ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, methodology): “ferently weighted variables, a simplified version known as sPESI (Table 7) has been developed and validated.(218,219) In patients with”
• American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. (2020, background): “Conceptually, the therapeutic management of patients with a new diagnosis of VTE can be divided into 3 phases: (1) initial management, which occurs from the time of diagnosis through the first 3 weeks of therapy; (2) primary treatment, which is a time-limited phase that typically runs for a minimum ”
• [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, positive): “ferently weighted variables, a simplified version known as sPESI (Table 7) has been developed and validated.(218,219) In patients with PE, the sPESI was reported to quantify their 30-day prognosis”
• Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. (2012, background): “We do not propose that echocardiography or cardiac biomarkers are measured routinely in all patients with PE, or in all patients with a non–low-risk PESI assessment.(122,127,149) This is because, when measured routinely, the results of these assessments do not have clear therapeutic implications.”
• 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, methodology): “In view of the complexity of the original PESI, which includes 11 differently weighed variables, a simplified version (sPESI; Table 7) has been developed and validated.(229) 231 As with the original version of the PESI, the strength of the sPESI lies in the reliable identification of patients at low”